Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia

Authors:

Abstract
Epigenetic drugs can overcome resistance to monoclonal antibodies in T-PLL and activate therapeutic targets for antibody-drug conjugates.
Funding Information
  • National Cancer Institute (RO1-CA098472)
  • Lymphoma Research Foundation
  • Chemotherapy Foundation
  • Leukemia and Lymphoma Society
  • Gabrielle's Angel Foundation
  • Paul Calabresi Career Development (K12-CA132783-01)
  • Tobacco Settlement funds of PA

This publication has 64 references indexed in Scilit: